A. Bagher, Wedyan S. Alharbi, Lamees S. Gadi, Lenah S. Binmahfouz, Rawan H Hareeri
{"title":"沙特西部人群中华法林相关基因VKORC1和CYP2C9的等位基因变异","authors":"A. Bagher, Wedyan S. Alharbi, Lamees S. Gadi, Lenah S. Binmahfouz, Rawan H Hareeri","doi":"10.1177/0976500x231189351","DOIUrl":null,"url":null,"abstract":"To investigate the allele and genotype frequencies of the warfarin-related genes VKORC1 (-1639G>A), CYP2C9*2, and CYP2C9*3 among healthy Saudis. This cross-sectional study involved 125 unrelated healthy Saudis ages 18–60 years visiting the King Abdulaziz University Hospital (KAUH) in Jeddah, Western Saudi Arabia. The Oragene™ DNA saliva collection kits were used to collect and extract DNA from saliva samples. A polymerase chain reaction-restriction fragment length polymorphism analysis was used to detect the mutant alleles. Over 51.4% of the Saudi participants carried one or more mutant alleles. The frequency of the VKORC1 (-1639G>A) allele in Saudi was relatively high at 54.8%. The frequencies of the CYP2C9 allele were 19.6% and 54% for the CYP2C9*2 and CYP2C9*3 alleles, respectively, which are substantially more abundant than in other populations. The observed high frequencies of VKORC1 (-1639G>A) and CYP2C9*2 and CYP2C9*3 polymorphisms suggest that genetic testing should be considered before initiating warfarin therapy to predict the optimal initial dose of warfarin and minimize warfarin-related side effects.","PeriodicalId":16761,"journal":{"name":"Journal of Pharmacology & Pharmacotherapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2023-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Allelic Variants in the Warfarin-related Genes VKORC1 and CYP2C9 in a Western Saudi Population\",\"authors\":\"A. Bagher, Wedyan S. Alharbi, Lamees S. Gadi, Lenah S. Binmahfouz, Rawan H Hareeri\",\"doi\":\"10.1177/0976500x231189351\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"To investigate the allele and genotype frequencies of the warfarin-related genes VKORC1 (-1639G>A), CYP2C9*2, and CYP2C9*3 among healthy Saudis. This cross-sectional study involved 125 unrelated healthy Saudis ages 18–60 years visiting the King Abdulaziz University Hospital (KAUH) in Jeddah, Western Saudi Arabia. The Oragene™ DNA saliva collection kits were used to collect and extract DNA from saliva samples. A polymerase chain reaction-restriction fragment length polymorphism analysis was used to detect the mutant alleles. Over 51.4% of the Saudi participants carried one or more mutant alleles. The frequency of the VKORC1 (-1639G>A) allele in Saudi was relatively high at 54.8%. The frequencies of the CYP2C9 allele were 19.6% and 54% for the CYP2C9*2 and CYP2C9*3 alleles, respectively, which are substantially more abundant than in other populations. The observed high frequencies of VKORC1 (-1639G>A) and CYP2C9*2 and CYP2C9*3 polymorphisms suggest that genetic testing should be considered before initiating warfarin therapy to predict the optimal initial dose of warfarin and minimize warfarin-related side effects.\",\"PeriodicalId\":16761,\"journal\":{\"name\":\"Journal of Pharmacology & Pharmacotherapeutics\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2023-08-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pharmacology & Pharmacotherapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/0976500x231189351\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacology & Pharmacotherapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/0976500x231189351","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Allelic Variants in the Warfarin-related Genes VKORC1 and CYP2C9 in a Western Saudi Population
To investigate the allele and genotype frequencies of the warfarin-related genes VKORC1 (-1639G>A), CYP2C9*2, and CYP2C9*3 among healthy Saudis. This cross-sectional study involved 125 unrelated healthy Saudis ages 18–60 years visiting the King Abdulaziz University Hospital (KAUH) in Jeddah, Western Saudi Arabia. The Oragene™ DNA saliva collection kits were used to collect and extract DNA from saliva samples. A polymerase chain reaction-restriction fragment length polymorphism analysis was used to detect the mutant alleles. Over 51.4% of the Saudi participants carried one or more mutant alleles. The frequency of the VKORC1 (-1639G>A) allele in Saudi was relatively high at 54.8%. The frequencies of the CYP2C9 allele were 19.6% and 54% for the CYP2C9*2 and CYP2C9*3 alleles, respectively, which are substantially more abundant than in other populations. The observed high frequencies of VKORC1 (-1639G>A) and CYP2C9*2 and CYP2C9*3 polymorphisms suggest that genetic testing should be considered before initiating warfarin therapy to predict the optimal initial dose of warfarin and minimize warfarin-related side effects.